High serum carbohydrate antigen-125 (CA-125) level predicts poor outcome in patients with follicular lymphoma independently of the FLIPI score

. 2012 Jul ; 96 (1) : 58-64. [epub] 20120526

Jazyk angličtina Země Japonsko Médium print-electronic

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid22639051

Carbohydrate antigen-125 (CA-125) was established as a prognostic marker in cancer, especially in ovarian carcinoma. Many recent studies have also reported on the prognostic significance of CA-125 in patients with different types of lymphoma, but only a few studies have been carried out in patients treated with rituximab or high-dose therapy. The prognostic impact of CA-125 on a large cohort of patients with follicular lymphoma (FL) has not been studied. This study analyzed the prognostic significance of CA-125 levels in 116 prospectively enrolled patients with previously untreated FL. It showed that the CA-125 level at the time of treatment initiation correlates with the clinical stage, number of involved nodal areas, bulky disease, hemoglobin level, beta-2 microglobulin level, and lactate dehydrogenase level. Patients with CA-125 >35 U/mL had significantly shorter progression-free (p < 0.001) and overall (p = 0.025) survival rates. Cox regression analysis identified high CA-125 levels as a prognostic factor for overall (HR 3.04, p = 0.05) and progression-free (HR 3.55, p < 0.001) survival rates independent of FLIPI score variables. CA-125 levels may help to refine risk assessment in the modern immunotherapy era.

Zobrazit více v PubMed

Clin Oncol (R Coll Radiol). 1994;6(2):137 PubMed

Blood. 2006 Jan 1;107(1):265-76 PubMed

Int J Lab Hematol. 2010 Dec;32(6 Pt 2):582-9 PubMed

Eur J Cancer. 1990;26(7):858 PubMed

Br J Haematol. 1997 Aug;98(2):450-2 PubMed

Int J Gynecol Pathol. 1983;2(3):275-85 PubMed

Blood. 2006 Sep 1;108(5):1504-8 PubMed

Int J Hematol. 2010 Sep;92(2):246-54 PubMed

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):63-6 PubMed

Eur J Haematol. 2007 May;78(5):399-404 PubMed

Ann Oncol. 2004 Oct;15(10):1484-9 PubMed

Leuk Lymphoma. 2010 Sep;51(9):1754-7 PubMed

J Clin Oncol. 1999 Apr;17(4):1244 PubMed

Clin Adv Hematol Oncol. 2008 Jul;6(7):527-31 PubMed

J Clin Oncol. 1999 Aug;17(8):2499-505 PubMed

Blood. 2004 Sep 1;104(5):1258-65 PubMed

Gastric Cancer. 2012 Apr;15(2):154-61 PubMed

Ann Oncol. 2009 Oct;20(10):1697-702 PubMed

J Clin Oncol. 2005 Aug 1;23(22):5019-26 PubMed

J Egypt Natl Canc Inst. 2009 Sep;21(3):209-17 PubMed

Haematologica. 1998 Sep;83(9):800-11 PubMed

N Engl J Med. 1983 Oct 13;309(15):883-7 PubMed

N Engl J Med. 1993 Apr 8;328(14):1002-6 PubMed

Ann Oncol. 2000 Nov;11(11):1485-91 PubMed

Int J Biol Markers. 2008 Oct-Dec;23(4):207-13 PubMed

Cancer Prev Res (Phila). 2011 Sep;4(9):1356-9 PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...